Clinical trials recruiting for Colorectal Neoplasms
61
Recruiting trials
41
US states with sites
40
Countries
16%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Bevacizumab | 7 |
| Cetuximab | 4 |
| Oxaliplatin | 3 |
| 5-Fluorouracil | 2 |
| Amivantamab | 2 |
| Irinotecan | 2 |
| Leucovorin calcium/Levoleucovorin | 2 |
| Trastuzumab | 2 |
| Tucatinib | 2 |
| 5 FU bolus | 1 |
| 5 FU continuous | 1 |
| 5-Fluorouracil (5-FU) | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 12 |
| Florida | 12 |
| New York | 10 |
| Texas | 10 |
| Arizona | 9 |
| Michigan | 9 |
| Colorado | 8 |
| Maryland | 8 |
| Virginia | 7 |
| Indiana | 6 |
| Missouri | 6 |
| North Carolina | 6 |
Top cities
Houston, Texas 10New York, New York 10Grand Rapids, Michigan 8Aurora, Colorado 7Nashville, Tennessee 6Dallas, Texas 5Detroit, Michigan 5Indianapolis, Indiana 5Portland, Oregon 5Rochester, Minnesota 5
Self-screener
Recruiting trials
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- A Novel Oral Synbiotic Formula in Reducing Advanced Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers
- A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- A Study of DM002 in Patients With Advanced Solid Tumors
- A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
- A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
- A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- AI-Based Stool Image Analysis for Colorectal Neoplasia Risk Assessment
- AP-NOSES: A Prospective Multicentre Registry of Natural Orifice Specimen Extraction in Minimally Invasive Colorectal Surgery
- Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer
- Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- Colorectal Metastasis Prevention International Trial 2
- DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies
- DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
- DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
- DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
- Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
- Diagnostic Accuracy of a Panel of Bacterial Gene Markers (M3) for Colorectal Advanced Neoplasia
- Early Detection of Advanced Adenomas and Colorectal Cancer
- Early Feeding Versus Delayed Feeding After Colorectal Endoscopic Submucosal Dissection
- Early Onset Colorectal Cancer Detection
- Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
- Epidemiological and Molecular Colorectal Cancer Registry
- Establishment of a Tumor Bank for Blood Samples
- Establishment of a Tumor Bank for Tissue Samples
- HTL0039732 in Participants With Advanced Solid Tumours
- Health Behavior Change in High-Risk Colorectal Cancer Individuals
- Impact of SMS Messaging on Participation in Colorectal Cancer Screening
- Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers
- Institut Paoli Calmettes Colorectal Cancer Database
- Linked-Color Imaging Versus Indigo Carmine Pump Spraying on the Colorectal Adenoma Detection Rate
- Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
- Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia
- Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status
- Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
- Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
- PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
- PRE-ISPY Phase I/II Oncology Platform Program
- PRIORITY-CONNECT 2 Trial
- Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)
- Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
- Predicting Colorectal Cancer - Tissue Samples to Evaluate Tumour Characteristics and Treatment Response
- Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance
- Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
- Serial Gut Microbiome and Bacterial Gene Markers Changes After Endoscopic Resection of Colorectal Advanced Neoplasia
- Smart Measurement of Circulating Tumor DNA
- Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
- Tailoring Treatment in Colorectal Cancer
- The GEOLynch Cohort Study
- The Impact of Laparotomy and Analgesia Methods on Diaphragm
- The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
- ULTRA-high-risk Surveillance to Avoid Future Events: the ULTRA-SAFE Trial
Related conditions
Trials recruiting for Colorectal Neoplasms often also study these conditions. Each links to its own recruiting-trial list.
Colorectal cancer 1359Lung cancer 2180Pancreatic cancer 870Ovarian Neoplasms 18Breast cancer 2239Breast Neoplasms 105Stomach Neoplasms 11Lung Neoplasms 33Esophageal Neoplasms 7Colorectal Adenoma 13
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Colorectal Neoplasms trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.